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Abstract
Background: Thymidine phosphorylase (TP) is identical with platelet-derived endothelial cell
growth factor (PD-ECGF) which promotes angiogenesis. The aim of this study was to evaluate the
cytosol activity of TP in tumor samples from patients with endometrial cancer.
Methods: The activity of TP was measured by the spectrophotometric method in the cytosol of
endometrial tumor samples from 43 patients. Moreover, the expression of platelet-derived
endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) protein and microvessel
density (MD) were examined in the same endometrial tumor samples by immunohistochemical
staining. Normal endometrium from 16 women, treated surgically due to nononcological reasons
served as a control.
A relationship between the cytosol TP activity, PD-ECGF/TP protein expression, MD and
clinicopathologic features was investigated.
Results: A significantly higher the cytosol TP activity, PD-ECGF/TP protein expression and MD
was stated in malignant tumor samples when compared to the control (samples of normal
endometrium). A positive statistically significant correlation between the cytosol enzyme activity
and PD-ECGF/TP protein expression and MD was found, but weaker from the remaining ones
between PD-ECGF/TP protein expression and MD was observed.
Besides no correlation between the cytosol TP activity, PD-ECGF/TP protein expression as well as
MD and grading or histopatological type of endometrial cancer was stated.
Conclusion: The cytosol TP activity in endometrial cancer is significantly higher than in normal
endometrium, with no relation as to the stage and grade of tumors, but correlates with the PD-
ECGF/TP protein expression and MD may therefore be associated with favorable prognosis in
patients treated with chemo- or radiotherapy after surgery.
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Background
Thymidine phosphorylase (TP: EC 2.4.2.4.) catalyses the
reversible phosphorolysis of thymidine to thymine and 2-
deoxyribose-1-phosphate [1]. TP is identical with platelet-
derived endothelial cell growth factor (PD-ECGF) which
promotes angiogenesis [1-6]. TP activity, PD-ECGF/TP pro-
tein and PD-ECGF/TP gene expression are significantly
increased in tumor tissues as compared to the adjacent non-
neoplastic tissues in a variety of human carcinomas [7-9]. In
certain tumors a high TP activity, as well as a high of PD-
ECGF/TP protein and PD-ECGF/TP gene expression are asso-
ciated with unfavorable prognosis [10-12]. On the other
hand, the high TP activity and the PD-ECGF/TP protein
expression are suggested to be useful prognostic factors for
tumors treated with chemotherapy or radiotherapy [13-15].
Endometrial carcinoma is one of the most common
malignancies of the female genital tract. The increase of
cytosol TP activity and a higher PD-ECGF/TP protein and
PD-ECGF/TP gene expression as compared to the adjacent
non-neoplastic tissues were reported in other gynecologic
malignancies [9,16-18]. The data on PD-ECGF/TP protein
expression and its correlation with microvessel density
(MD) in endometrial cancer are controversial [19-21]. The
cytosol TP activity and its correlation with MD in endome-
trial cancer has not been carried out so far.
The aim of the study was also to evaluate the influence of
the cytosol TP activity and PD-ECGF/TP protein expres-
sion on the intensity of angiogenesis in malignant tumors
enabling prognosis and choice of the proper therapy for
patients with endometrial cancer after surgery.
Methods
Patients
This study included 43 patients with histologically con-
firmed endometrial tumors who underwent surgery at the
Department of Gynecologic Oncology, Medical Univer-
sity of Łódź in Poland during the period from 2002 to
2005. No patient had received any therapy before surgery.
All patients with adenocarcinoma were postmenopausal,
aged between 50 to 88 years (mean age = 60). 16 women
aged 32 – 44 years with normal endometrium, treated sur-
gically (7 women were in the luteal and 9 were in follicu-
lar phase of the menstrual cycle) due to nononcological
reasons served as a control.
The patients were staged according to the criteria recom-
mended by the International Federation of Gynecology
and Obstetrics (FIGO) [22]: stage I, n = 29; stage II, n = 7:
stage III, n = 7. The tumors were histologically classified
into three grades [23]: G-1, n = 18; G-2, n = 19; G-3, n = 6.
Histology and immunohistochemistry
For histology hematoxillin and eosin staining were per-
formed. For the immunohistochemistry staining, rou-
tinely processed, formalin-fixed, paraffin embedded,
tissue blocks were cut on silanized slides.
Microvessel assessment was performed using a mouse
anti-human CD31 (Dako) antibody in dilution 1:40 with
streptavidin-biotin technique following prolonged (13
min) enzymatic digestion with trypsin. Microvessel
counting, performed according to the Weidner's method
[24] was initiated in the areas of most intensive vasculari-
zation (hot-spots) identified by scanning of the speci-
mens at low power magnification. Counting was
continued in ten consecutive high power fields (400×).
Immunohistochemical staining for PD-ECGF/TP protein
was performed using the anti-TP mouse monoclonal anti-
body NCL-PDEGF clone P-GF.44C (NovoCastra) in dilu-
tion 1:30 [25]. The extent of immunohistochemical
expressions of PD-ECGF/TP protein of specimens was
classified into 0, 1, 2, 3 grades. Specimens graded as 1, 2,
3 were regarded as positively stained and those graded as
0 as negatively stained. We assumed cases as positive in
which we observed more then 5% positively stained cells
under high power magnification. However, in a part of
cases we observed a significant heterogeneity of expres-
sion in tumor (two cellular populations mixed with/with-
out expression). Then we accepted only these tumors as
positive in which the percentage of positive fields
amounted to over 5% of the whole tumor.
Preparation of the cytosol fraction
Tissue samples (approximately 2 g) were dissected from
tumors immediately following surgery and frozen at low
temperature (-80°C) until required. Nonneoplastic
endometrial samples were frozen, too. Both kinds of spec-
imens were studied in the same conditions with the aid of
the following methods: Tissue samples were homoge-
nized in Ultra/turrax T 25 in 4 vol. of ice cold buffer (1
mM EDTA, 0.02% mercaptoethanol, 2 mM phenylmeth-
anesulfonyl fluoride (PMSF), 10 mM tris (Hydroxyme-
thyl) aminomethane – maleate, pH 6,5), with 10%
glycerol and then centrifuged at 100 000 × g for 1 h, to
obtain the cytosol fraction. It was then pooled and directly
taken for analysis.
Enzyme assay
TP activity was assessed by the spectrophotometric
method described by Yoshimura et al. [7] in our own
modification [16] using the transformation of thymine
(T) from thymidine (dThd) in the presence of arsenate.
The incubation mixture of 0.5 ml final volume contained
0.1 M tris (hydroxymetyl) aminomethane-arsenate buffer
(pH 6.5), 10 mM dThd and appropriate volume of the
cytosol fraction. After a 1 h incubation at 37°C, the reac-
tion was stopped by adding 0.5 ml 1 N NaOH and the
thymine formed was measured with absorbance at 300
nm. The protein content was determined according to theJournal of Experimental & Clinical Cancer Research 2008, 27:64 http://www.jeccr.com/content/27/1/64
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method described by Bradford [26]. The activity of TP was
determined in micromoles of thymine released during 1 h
per milligram of protein.
Statistical analysis
The p < 0.05 was taken as the level of statistical signifi-
cance. Univariate and multiple linear regression was used
to analyse the data. All stastistical analyses were per-
formed using a statistical software STATA 6.
Results
Activity of TP
TP activity was assessed by the spectrophotometric
method described by Yoshimura et al. [7] in our own
modification [16]. A significantly higher TP activity was
stated in the cytosol of tumor samples from 43 endome-
trial cancer patients when compared to the control (nor-
mal endometrium from 16 women). The mean activity of
TP measured in micromoles of T × mg protein-1 × h-1 in the
cytosol from tumor samples it was 2.92 ± 1.96 (0.71 –
9.14) and from normal endometrial samples was 0.50 ±
0.27 (0.11 – 1.07) with p < 0.001 (Figure 1A).
Expression of TP/PD-ECGF protein
Microscopic features of specimens expressing PD-ECGF/
TP protein are shown in figure 2 and 3. The extent of
immunohistochemical expressions of PD-ECGF/TP pro-
tein of the specimens was classified into 0, 1, 2, 3 grades.
Staining in endometrial tumor cells was mainly found in
cytoplasm, sometimes in endothelial nuclei and part of
stroma, possibly macrophages, granulocytes and fibrob-
lasts (Figure 2.). From among the mentioned cells we only
assessed epithelial ones. A significantly higher mean
expression of PD-ECGF/TP protein was also stated in
tumor samples from the endometrial cancer patients
when compared to the control – samples from patients
with normal endometrium (Figure 3): 1.24 ± 1.11 (0.00 –
3.00) and 0.23 ± 0.43 (0.00 – 1.00), respectively, with p =
0.001 (Figure 1B), measured as described in Methods.
Microvessel density
Microvessel counting, according to the Weidner's method
[24] was initiated in the areas of most intensive vasculari-
zation (hot-spots) identified by scanning of the speci-
mens at low power magnification (100×, Figure 4).
Counting was continued in ten consecutive high power
fields (400×). Control (normal endometrium) was the
region with lower MD. MD in malignant tumors had a sig-
nificantly higher value of microvessels: 67.18 ± 27.14
(24.00 – 117.3), in comparison with normal
endometrium, where it attained the value 29.02 ± 9.64
(18.00 – 49.40) with p < 0.000001 (Figure 1C).
Correlations
A correlation between the cytosol TP activity and PD-
ECGF/TP protein expression and MD in malignant tumor
samples of patients with endometrial cancers has been
studied. A statistically significant positive correlation
between the cytosol TP activity and PD-ECGF/TP protein
expression (p = 0.0035, R = 0.4858; Figure 5.) was stated.
A correlation between the cytosol TP activity and MD was
also statistically significant (p = 0.0286, R = 0.3649; Figure
6), but weaker correlation between PD-ECGF/TP protein
expression and MD (p = 0.0429, R = 0.3492 according to
Spearman) was observed.
The consecutive statistical analysis was meant to find a
correlation between the activity of the studied enzyme
and clinical stages of endometrial cancer (assessed acc. to
FIGO). As it follows from the presented data (Table 1) the
cytosol TP activity is lower in more advanced neoplastic
lesions (FIGO II and FIGO III versus FIGO I), however, no
statistically significant dependence, has been found
between the cytosol TP activity and clinical stages (p =
0.3471, R = -0.1487 – according to Spearman – Table 2).
Similar observation and lack of correlation was stated for
the expression of PD-ECGF/TP protein and clinical stages
(p = 0.3323, R = 0.1594) and for MD and clinical stages of
endometrial cancer, (p = 0.3057, R = -0.1639 – Table 1
and 2).
The cytosol TP activity, PD-ECGF/TP protein expression
and MD were studied according to the histopathological
degree of differentiation (Table 1). No statistically signifi-
cant relation between the TP activity and grading (p =
0.0789, R = 0.2741), between the expression of PD-ECGF/
TP protein (p = 0.1792, R = -0.2166) and between MD
and grading of endometrial tumors (p = 0.5922, R = -
0.0851) (Table 2) has been found.
No statistically significant relation between TP activity,
PD-ECGF/TP protein expression, MD and age and tumor
diameters of patients was concluded, either (data not pub-
lished).
Discussion
Thymidine phosphorylase (TP) is identical with platelet-
derived endothelial cell growth factor (PD-ECGF) which
promotes angiogenesis [2-6]. The aim of our study was to
evaluate the cytosol activity of TP together with its protein
level (PD-ECGF/TP protein expression) in relation to the
intensity of angiogenesis in endometrial cancer.
Fourty three patients with endometrial malignant tumor
were included in the study. The control was the normal
endometrium obtained from sixteen patients. The
enzyme activity was measured in the cytosol from tumor
and normal tissues using the spectrophotometric method
and expressed in micromoles of thymine released during
1 h per milligram of protein. A significantly higher mean
cytosol TP activity was stated in these malignant tumors as
compared to the control. We obtained similar observa-Journal of Experimental & Clinical Cancer Research 2008, 27:64 http://www.jeccr.com/content/27/1/64
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The cytosol TP activity, PD-ECGF/TP – protein expression and microvessel density in tumor (T) and normal endometrium (E) Figure 1
The cytosol TP activity, PD-ECGF/TP – protein expression and microvessel density in tumor (T) and normal 
endometrium (E). Results are expressed as mean ± SD (standard deviation), p < 0.001. A.) TP activity – The cytosol TP 
activity measured in micromoles of T × mg protein-1 × h-1 as described in Materials and Methods. Tumor samples were from 43 
endometrial cancer patients and normal endometrium from 16 women treated surgically due to nononcological reasons. B.) 
TP/PDECGF – PD-ECGF/TP – protein expression; The extent of immunohistochemical expressions was classified into 0, 1, 2, 
3 grades as described in Materials and Methods. C.) MD – Microvessel density. Microvessel counting, performed according to 
the Weidner's method [24] measured as described in Materials and Methods.
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tions for cytosol TP activity from ovarian [17] and breast
carcinoma [16]. In benign and mixed uterine tumors [9]
we also found a significantly higher mean TP activity (in
the cytoplasmatic soluble fraction obtained at 50 000 × g
and in partially purified fraction after DEAE-Sepharose)
from only those women who were in the follicular phase
of the cycle during surgery as compared to the control
(myometrium), although the obtained TP activity values
did not differ in the normal myometrium from women
who were in luteal and in follicular phase of the menstrual
cycle during surgery [9]. In our present data no statistically
significant dependence has been found between the
cytosol TP activities in normal endometrium in both
phases of the menstrual cycle, either (data not published).
Our results are in agreement with these obtained by Take-
bayashi et al. [8] for several human solid tumors. TP activ-
ity was measured in tissue homogenate using the same
spectrophotometric method as ours and expressed in
micromoles of thymine released during 1 h per milligram
of protein and was significantly higher in carcinomas of
oesophagus, stomach, colorectum, pancreas and lung
than in the adjacent non-neoplastic tissue. On the con-
trary, there was no significant difference between the TP
activity in carcinoma of liver and thyroid and than in the
control materials [8]. The high TP activity in tumors was
associated with unfavorable prognosis [10-12], but there
were published data that in patients treated with chemo-
therapy this high TP activity might contribute to better
prognosis [13,14].
Immunohistochemical staining for PDECGF/TP protein expression in endometrial cancer Figure 2
Immunohistochemical staining for PDECGF/TP protein expression in endometrial cancer. Immunohistochemical 
staining for PD-ECGF/TP protein was performed using the anti-TP mouse monoclonal antibody NCL-PDEGF clone P-GF.44C 
(NovoCastra) The cytoplasmic and only occasional nuclear staining of cancer cells is seen (note negative squamous metaplastic 
cells in the center). On the right normal endometrial cells. (200×).Journal of Experimental & Clinical Cancer Research 2008, 27:64 http://www.jeccr.com/content/27/1/64
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The enzyme was measured using the spectrophotometric
method and expressed in nanomoles of 5-fluorouracil (5-
FU) released during 1 minute per mg protein in the
cytosol from cervical cancer (n = 20), leiomyoma (n = 23),
ovarian cancer (n = 46), ovarian endometriosis (n = 21)
benign epithelial ovarian tumor (n = 27) and also from
endometrial cancer tissues (n = 26) [27]. This study indi-
cated that he mean activity in endometrial cancer tissues
was significantly higher (64,5 nanomoles of 5-FU × mg
protein-1 × minute-1) than in the corresponding normal
tissues (27,5 nanomoles of 5-FU × mg protein-1 × minute-
1[27].
We have also measured the expression of PD-ECGF/TP
protein in the endometrial cancer and normal
endometrium using an immunohistochemical technique
with the P-GF-44C monoclonal antibody. In our study the
staining was mainly found in cytoplasm, sometimes
endothelial nuclei and part of stroma. Our observations
are similar with these obtained by Fujiwaki et al. for
endometrial cancer [28]. In our study the expression of
PD-ECGF/TP protein was statistically higher in endome-
trial cancer as compared to the control. No expression was
detected in coexisting normal endometrial stroma or
stroma of endometriosis either [29]. Immunohistochem-
ical staining with a monoclonal antibody against TP was
also used in the study of the cancerous oesophagus, stom-
ach, colon, bladder, pancreas and lung, and the propor-
tion of TP-postive tumors was also significantly higher
than that of the TP-positive adjacent normal tissues [8].
However our results remain in controversy with those
obtained by Sivridis et al. [30] who found a poor expres-
Immunohistochemical staining for PDECGF/TP protein in normal endometrium Figure 3
Immunohistochemical staining for PDECGF/TP protein in normal endometrium. Immunohistochemical staining 
for PD-ECGF/TP protein was performed using the anti-TP mouse monoclonal antibody NCL-PDEGF clone P-GF.44C (Novo-
Castra) (200×).Journal of Experimental & Clinical Cancer Research 2008, 27:64 http://www.jeccr.com/content/27/1/64
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sion of TP in endometrial carcinoma. They reported, that
immunopositiveness for PD-ECGF/TP was increased in a
small proportion of endometrial carcinomas (approxi-
mately 5%) and up-regulation occurred predominantly at
the invading tumor front which is probably induced by
cytokines of histocystic and lymphocytic origin [30].
Takebayashi et al. [8] assayed the expression of PD-ECGF/
TP protein and the activity of TP in the same human solid
tumor specimens and found a correlation between them
[8]. Little is known of TP activity in endometrial cancers
except for the works of Kamoi et al. [31] (article and
abstract in Japanase) and Suzuki [27]. Thus we have stud-
ied spectrophotometrically the cytosol TP activity in
tumor samples and tested if it is correlated with immuno-
histochemically studied expression of PD-ECGF/TP pro-
tein in the same cases of well-differentiated endometrial
carcinomas. Our study revealed that the expression of PD-
ECGF/TP protein was correlated with the cytosol activity
of TP in the same endometrial cancer, and this correlation
was statistically significant.
In endometrial cancer a high microvessel count is an inde-
pendent prognostic factor [32-34] as it has relation to
metastases [35]. However, Seki et al. [36] reported, that
MD was not associated with lymph node metastasis or
surgical stage and therefore angiogenesis does not neces-
sarily contribute to metastasis in endometrial cancer [36].
Abulafia et al. [37] reported that angiogenesis was
increased in complex endometrial hyperplasia as com-
pared to controls of simple hyperplasia. The angiogenic
capability of complex hyperplasia was comparable to the
FIGO stage Ia endometrial cancer. An increased angiogen-
esis was found in cases of invasive (stages Ib and Ic)
Immunohistochemical staining for microvessel density (MD) in endometrial cancer Figure 4
Immunohistochemical staining for microvessel density (MD) in endometrial cancer. Microvessel assessment was 
performed using a mouse anti-human CD31 (Dako) antibody (100×).Journal of Experimental & Clinical Cancer Research 2008, 27:64 http://www.jeccr.com/content/27/1/64
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endometrial cancer as compared to complex hyperplasia
or stage Ia endometrial cancer [37]. Fujiwaki at al. [38]
found that the immunohistochemical expression of TP
was associated with the increase of MD as an index of ang-
iogenesis in endometrial cancer, which suggested that TP
might play an important role in angiogenesis [38]. In our
study MD attained a significantly higher value in endome-
trial cancer in comparison with normal endometrium.
Our data confirmed the correlation between MD and the
cytosol TP activity and revealed the weaker of such a cor-
relation between MD and PD-ECGF/TP protein expres-
sion in endometrial cancer, indicating that the active
enzyme but not its protein influences in some way the ves-
sel development i.e. that variety of factors may influence
the activation of enzymatic protein. A high PD-ECGF/TP
protein expression accompanying the high cytosol TP
activity may concern also the cases of its localization in
stroma. Also Sakamoto et al. [29] showed that immuno-
histochemical PD-ECGF/TP expression was predomi-
nantly observed in tumor stroma, and that TP-positive
cells in the stroma are probably macrophages and plasma
cells [29]. Seki et al. [36] found, that PD-ECGF production
within cancer cells was not so strong as in the stroma cells
and there was no correlation between the expression of
PD-ECGF in cancer cells and any clinicopathological vari-
ables including microvessel count [36]. Another study
failed to find a relationship between PD-ECGF expression
and angiogenesis either [39]. In the study of Sivridis et al.
[40] the expression of PD-ECGF in tumor cells did not
effectively contribute to the angiogenic process and was
deprived of any practical significance since no relation-
ship was found between this expression and the his-
topathological factor examined, but was associated with
aggressive histological features endometrial carcinomas
[40]. In our study in endometrial cancer revealed no sig-
nificant correlation between the cytosol TP activity, PD-
The correlation between the cytosol TP activity and expression of PD-ECGF/TP protein in endometrial cancer Figure 5
The correlation between the cytosol TP activity and expression of PD-ECGF/TP protein in endometrial can-
cer. p = 0.0035, R = 0.4858, statistical analysis according to Spearman (measured as described in Materials and Methods).
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ECGF/TP protein expression, MD and histopathological
factors. Our results were in agreement with these obtained
by Suzuki at al. [27]. There were no significant differences
in the cytosol enzyme activity according to tumor stage
classification. When assessed according to histopatho-
logic degree of differentiation, the enzyme activity
appeared to be higher in pathologic grade G – 3 than in
grade G – 1 and G – 2, but this difference did not show sig-
nificance [27]. We found that TP activity in tumor was
higher in grade G – 2 than that obtained in G – 1 and G –
3 and this difference did not show significance either. The
same concerns PD-ECGF protein expression. Our results
are in conformity with these obtained by Mazurek et al.
[41] who found no statistically significant correlation
between TP immunohistochemical expression and his-
topatological grade and FIGO stage, but particular FIGO
stages showed a significant trend of increasing TP
endometrial cancer overexpression [41]. We also found
that PD-ECGF/TP protein expression was higher in FIGO
stage II and III vs I, but there were no significant differ-
ences, either.
The mechanism of endometrial angiogenesis involves
stimulation by ovarian steroids of production of ang-
iogenic regulators by endometrial epithelium and stroma
which then act on the endothelium [42]. Endothelial cells
are the principal actors in angiogenesis, which after effect-
ing the proteolytic degradation of the basemant mem-
branes, migrate through the membrane to form sprouts
[43]. 2-deoxy-D-ribose generated by PD-ECGF/TP catalyz-
ing phosphorolysis of thymidine, stimulates endothelial
cell migration [1,44] via a mechanistic pathway similar to
that described for glucose that attracts endothelial cells
along its concentration gradient [45]. However, Brown et
al. suppose, that 2-deoxy-D-ribose induces cellular oxida-
tive stress, which generates oxygen radicals during early
The correlation between the cytosol TP activity and microvessel density (MD) in endometrial cancer Figure 6
The correlation between the cytosol TP activity and microvessel density (MD) in endometrial cancer. p = 
0.0286, R = 0.3649, statistical analysis according to Spearman (measured as described in Materials and Methods).
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stages of protein glycation and promotes secretion of ang-
iogenic factors [46,47]. Moreover, it was suggested that,
beside 2-deoxy-D-ribose, thymine might also exhibit ang-
iogenic properties stimulating the effects of other growth
factor [48]. The extent to which TP is implicated in neoan-
giogenesis is far from being fully elucidated [49].
Although the mechanism of TP induction is not yet com-
pletely clear, but TNF, IL10 and other cytokines have been
clearly shown to induce its expression. The various com-
plex interactions of TP give it an essential role in cellular
functioning and, hence, it is an ideal target in cancer ther-
apy [50].
Conclusion
Our results indicate, that the cytosol TP activity together
with PD-ECGF/TP protein expression is higher in
endometrial cancer when compared to normal
endometrium and is correlated with angiogenesis. It sug-
gests, that appropriately modulated TP activity may be an
interesting target for a novel cancer drug in endometrial
cancer. The study of TP activity together with PD-ECGF/TP
expression and its correlation with angiogenesis may con-
tribute to a proper choice of therapy for patients with
endometrial cancer.
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